All In Biotech

Drug Trial Radar · NCT06596005

Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsule in Patients With Early-stage Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Sep 18, 2024

Primary completion

Sep 3, 2025

Study completion Sep 9, 2025

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Taizhou Hospital; Wenzhou Central Hospital; Sir Run Run Shaw Hospital; The Second Affiliated Hospital of Jiaxing University; Hangzhou PhecdaMed Co., Ltd.; Huzhou Central Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo parallel-controlled Phase II clinical trial to evaluate the efficacy and safety of TJ0113 capsule in patients with early-stage Parkinson's disease

Conditions

  • Parkinson Disease

Interventions

  • TJ0113 200mgDrug

    200 mg Capsule, Once Daily

  • TJ0113 400mgDrug

    400 mg Capsule, Once Daily

  • PlaceboDrug

    Capsule, Once Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline in Scores of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) in Subjects After 12 Weeks of Treatment.Evaluation Time Point: ≥ 12 Hours From the Most Recent Dose of Anti-PD Drug.Time frame: After 12 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Second Affiliated Hospital, School of Medicine, Zhejiang University, China

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.